Xconomy -- HemaQuest Pharmaceuticals, the developer of new treatments for blood diseases, has named John Longenecker as its new CEO, replacing Ron Berenson, according to a report in TechFlash. Longenecker was formerly the CEO of San Diego-based Favrille, the developer of an immune boosting therapy for cancer. HemaQuest will now likely have offices in San Diego and Seattle, Longenecker said in an e-mail to TechFlash. HemaQuest most recently made news when it closed on a $16 million financing round in July.
